

# Kensei Tobinai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6156495/publications.pdf>

Version: 2024-02-01

130  
papers

12,039  
citations

76196

40  
h-index

25716

108  
g-index

132  
all docs

132  
docs citations

132  
times ranked

10486  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study â€” JCOG0108A. Journal of Clinical and Experimental Hematopathology: JCEH, 2021, 61, 35-41.	0.3	0
2	A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Advances, 2021, 5, 984-993.	2.5	9
3	Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide+rituximab (R2) vs. rituximab+placebo in relapsed/refractory indolent non-Hodgkin lymphoma. International Journal of Hematology, 2020, 111, 409-416.	0.7	6
4	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. Expert Opinion on Drug Safety, 2020, 19, 1105-1120.	1.0	6
5	<p>Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma</p>. OncoTargets and Therapy, 2020, Volume 13, 5993-6009.	1.0	9
6	Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study. International Journal of Hematology, 2019, 109, 366-368.	0.7	4
7	Development of new agents for peripheral T-cell lymphoma. Expert Opinion on Biological Therapy, 2019, 19, 197-209.	1.4	26
8	Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. Cell Reports, 2019, 29, 2321-2337.e7.	2.9	100
9	Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Drugs in Context, 2019, 8, 1-14.	1.0	29
10	Adult T-Cell Leukemia-Lymphoma. Cancer Treatment and Research, 2019, 176, 145-161.	0.2	4
11	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	6.3	517
12	Targeting EZH2 with tazemetostat. Lancet Oncology, The, 2018, 19, 586-587.	5.1	24
13	A Review of New Findings in Adult T-cell Leukemiaâ€”Lymphoma: A Focus on Current and Emerging Treatment Strategies. Advances in Therapy, 2018, 35, 135-152.	1.3	72
14	Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor. Lancet Haematology,the, 2018, 5, e134-e135.	2.2	5
15	Antibody therapy targeting CD19 for B-cell non-Hodgkinâ€™s lymphoma. Annals of Oncology, 2018, 29, 1086-1089.	0.6	16
16	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	0.6	124
17	Partial deletion of the <sc>ALK</sc> gene in <sc>ALK</sc>-positive anaplastic large cell lymphoma. Hematological Oncology, 2018, 36, 150-158.	0.8	7
18	Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. OncoTargets and Therapy, 2018, Volume 11, 2287-2293.	1.0	27

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. <i>International Journal of Hematology</i> , 2018, 108, 499-509.	0.7	9
20	Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 736-742.	0.6	3
21	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. <i>Advances in Therapy</i> , 2017, 34, 324-356.	1.3	128
22	Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 239-253.	0.9	32
23	Disease-oriented treatment of T-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 54-59.	0.8	4
24	Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. <i>Cancer Science</i> , 2017, 108, 1109-1118.	1.7	91
25	Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance. <i>International Journal of Hematology</i> , 2017, 106, 522-532.	0.7	28
26	Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey. <i>Cancer Science</i> , 2017, 108, 2478-2486.	1.7	63
27	Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. <i>Cancer Science</i> , 2017, 108, 2022-2029.	1.7	55
28	Rituximab biosimilars: introduction into clinical practice. <i>Lancet Haematology</i> , the, 2017, 4, e342-e343.	2.2	2
29	Mogamulizumab for the treatment of T-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1145-1153.	1.4	28
30	Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. <i>Cancer Science</i> , 2016, 107, 1785-1790.	1.7	19
31	Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2016, 104, 396-399.	0.7	6
32	Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden. <i>International Journal of Hematology</i> , 2016, 104, 700-708.	0.7	7
33	Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. <i>Journal of Clinical Oncology</i> , 2016, 34, 4086-4093.	0.8	123
34	Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2016, 104, 236-244.	0.7	17
35	Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. <i>International Journal of Hematology</i> , 2016, 103, 86-94.	0.7	28
36	Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. <i>Lancet Haematology</i> , the, 2016, 3, e107-e118.	2.2	48

#	ARTICLE	IF	CITATIONS
37	t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. <i>Blood Cancer Journal</i> , 2015, 5, e285-e285.	2.8	33
38	Integrated molecular analysis of adult T cell leukemia/lymphoma. <i>Nature Genetics</i> , 2015, 47, 1304-1315.	9.4	659
39	Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. <i>British Journal of Haematology</i> , 2015, 169, 672-682.	1.2	218
40	Human T-cell Lymphotropic Virus Type 1-Associated Adult T-cell Leukemia-Lymphoma: New Directions in Clinical Research. <i>Clinical Cancer Research</i> , 2014, 20, 5217-5225.	3.2	68
41	A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 768-776.	1.2	104
42	Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). <i>British Journal of Haematology</i> , 2014, 166, 739-748.	1.2	79
43	Subcutaneous rituximab: a practical approach?. <i>Lancet Oncology</i> , The, 2014, 15, 254-255.	5.1	3
44	Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context. <i>Clinical Cancer Research</i> , 2014, 20, 5173-5181.	3.2	9
45	An evaluation of mogamulizumab for the treatment of peripheral T-cell lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 735-742.	0.5	0
46	Adult T-cell Leukemia-Lymphoma. , 2014, , 99-110.		0
47	Adult T-Cell Leukemia-Lymphoma. , 2014, , 2076-2092.e4.		0
48	Biology and treatment of HTLV-1 associated T-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 3-14.	0.7	32
49	Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Cancer Science</i> , 2013, 104, 105-110.	1.7	31
50	HTLV-1-Associated T-cell Diseases. , 2013, , 113-135.		2
51	Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8506-8506.	0.8	11
52	Phase II Study of Intensive Post-remission Chemotherapy and Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Japan Clinical Oncology Group Study, JCOG9402. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 394-404.	0.6	5
53	Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 837-842.	0.8	581
54	Lymphoma Study Group of JCOG. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 85-95.	0.6	25

#	ARTICLE	IF	CITATIONS
55	Clinical Trials and Treatment of ATL. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-12.	2.0	29
56	Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan Clinical Oncology Group Study JCOG0211. <i>Journal of Clinical Oncology</i> , 2012, 30, 4044-4046.	0.8	123
57	Bcl-2, c-Myc, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. <i>Cancer Science</i> , 2012, 103, 1898-1904.	1.7	16
58	Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma. <i>BMC Cancer</i> , 2012, 12, 457.	1.1	34
59	Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 235-240.	1.2	43
60	Guest editorial: Management of malignant lymphoma is continuously improving. <i>International Journal of Hematology</i> , 2012, 96, 533-534.	0.7	0
61	Peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 6756-6767.	0.6	278
62	Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. <i>Cancer Science</i> , 2011, 102, 432-438.	1.7	25
63	Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study. <i>Cancer Science</i> , 2011, 102, 1698-1705.	1.7	21
64	Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3990-3998.	0.8	59
65	Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2010, 92, 563-570.	0.7	23
66	Phase I study of inotuzumab ozogamicin (CMC544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. <i>Cancer Science</i> , 2010, 101, 1840-1845.	1.7	55
67	Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>Cancer Science</i> , 2010, 101, 2059-2064.	1.7	61
68	Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. <i>Cancer Science</i> , 2010, 101, 2579-2585.	1.7	14
69	Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1591-1598.	0.8	351
70	Clinical Trials for Human T-Cell Lymphotropic Virus Type 1-Associated Peripheral T-Cell Lymphoma in Japan. <i>Seminars in Hematology</i> , 2010, 47, S5-S7.	1.8	9
71	Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches. <i>Expert Review of Hematology</i> , 2010, 3, 743-753.	1.0	19
72	Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2010, 51, 813-821.	0.6	30

#	ARTICLE	IF	CITATIONS
73	Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2009, 27, 453-459.	0.8	485
74	Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211. <i>Journal of Clinical Oncology</i> , 2009, 27, 5594-5600.	0.8	315
75	Japanese phase II study of <sup>90</sup> Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. <i>Cancer Science</i> , 2009, 100, 158-164.	1.7	35
76	Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. <i>Cancer Science</i> , 2009, 100, 54-61.	1.7	38
77	Phase I/II and pharmacokinetic study of cladribine with 2h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. <i>Cancer Science</i> , 2009, 100, 1344-1350.	1.7	7
78	Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. <i>Cancer Science</i> , 2009, 100, 1951-1956.	1.7	8
79	Current management of adult T-cell leukemia/lymphoma. <i>Oncology</i> , 2009, 23, 1250-6.	0.4	17
80	Adult T-Cell Leukemia-Lymphoma. , 2008, , 2425-2441.		4
81	Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results.. <i>Blood</i> , 2008, 112, 1007-1007.	0.6	3
82	Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-NHL: 7-year follow-up results. <i>Journal of Clinical Oncology</i> , 2008, 26, 8616-8616.	0.8	2
83	1/4 1/4 Žé“é„è...«āf»āfāfāfāf’è...«æ2»ç™,ā,ā@āf—āfāf†ā,ā,1/2āf1/4āf’è»ā°3ā% Bortezomibā°āŽā...¥1/4šè—1/4b ©ā«æD.ā«āŸeā		
84	4. Antibody Therapy for Malignant Lymphoma. <i>Internal Medicine</i> , 2007, 46, 99-100.	0.3	5
85	VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801. <i>Journal of Clinical Oncology</i> , 2007, 25, 5458-5464.	0.8	429
86	Revised Response Criteria for Malignant Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 579-586.	0.8	4,061
87	Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group study 9004. <i>Cancer Science</i> , 2007, 98, 1350-1357.	1.7	14
88	Proteasome inhibitor, bortezomib, for myeloma and lymphoma. <i>International Journal of Clinical Oncology</i> , 2007, 12, 318-326.	1.0	42
89	Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. <i>Cancer Science</i> , 2006, 97, 305-312.	1.7	28
90	Phase II Study of Oral Fludarabine Phosphate in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 174-180.	0.8	36

#	ARTICLE	IF	CITATIONS
91	Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2006, 17, 330-333.	0.6	7
92	Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Bortezomib (B) in Patients (pts) with Relapsed Multiple Myeloma (MM): A Phase I/II Study in Japan.. <i>Blood</i> , 2006, 108, 5106-5106.	0.6	2
93	Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibratumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. <i>Cancer Science</i> , 2005, 96, 903-910.	1.7	17
94	Clinical Trials for Malignant Lymphoma in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 369-378.	0.6	19
95	Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. <i>Annals of Oncology</i> , 2004, 15, 821-830.	0.6	99
96	t(11;18)-Bearing Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Responding to Cladribine. <i>International Journal of Hematology</i> , 2004, 80, 70-74.	0.7	1
97	Primary Mediastinal Large B-Cell Lymphoma: A Single-Institution Clinical Study in Japan. <i>International Journal of Hematology</i> , 2004, 79, 465-471.	0.7	11
98	EBV-Positive Burkitt Lymphoma as a Late-Onset Posttransplantation Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2004, 79, 387-389.	0.7	6
99	Treatment of Indolent Non-Hodgkin's Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone. <i>International Journal of Hematology</i> , 2004, 79, 311-321.	0.7	13
100	Two Entities of Precursor T-Cell Lymphoblastic Leukemia/Lymphoma Based on Radiologic and Immunophenotypic Findings. <i>International Journal of Hematology</i> , 2004, 80, 43-51.	0.7	15
101	Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas: Results of a Japanese Phase II Study. <i>International Journal of Hematology</i> , 2004, 80, 267-277.	0.7	40
102	A Randomized Controlled Trial Investigating the Survival Benefit of Dose-Intensified Multidrug Combination Chemotherapy (LSG9) for Intermediate- or High-Grade Non-Hodgkin's Lymphoma: Japan Clinical Oncology Group Study 9002. <i>International Journal of Hematology</i> , 2004, 80, 341-350.	0.7	15
103	Primary Mediastinal Lymphoma. <i>Journal of Computer Assisted Tomography</i> , 2004, 28, 782-789.	0.5	55
104	Deoxycoformycin-Containing Combination Chemotherapy for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study (JCOG9109). <i>International Journal of Hematology</i> , 2003, 77, 164-170.	0.7	91
105	Phase II Study of Cladribine (2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma. <i>International Journal of Hematology</i> , 2003, 77, 512-517.	0.7	44
106	Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 90-96.	1.1	1
107	Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma. <i>International Journal of Clinical Oncology</i> , 2003, 8, 212-223.	1.0	12
108	Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. <i>Annals of Oncology</i> , 2002, 13, 928-943.	0.6	127

#	ARTICLE	IF	CITATIONS
109	Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. <i>Annals of Oncology</i> , 2002, 13, 1347-1355.	0.6	48
110	ATL T-cell neoplasms: a clinicopathological study of 11 cases. <i>Annals of Oncology</i> , 2002, 13, 1792-1798.	0.6	33
111	Rituximab and other emerging monoclonal antibody therapies for lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2002, 7, 289-302.	1.0	10
112	Primary Hepatic Low-Grade B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: A Case Report and Review of the Literature. <i>International Journal of Hematology</i> , 2002, 75, 85-90.	0.7	44
113	Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan. <i>International Journal of Hematology</i> , 2002, 76, 411-419.	0.7	23
114	Detection of t(11;18) in MALT-Type Lymphoma With Dual-Color Fluorescence In Situ Hybridization and Reverse Transcriptase-Polymerase Chain Reaction Analysis. <i>Diagnostic Molecular Pathology</i> , 2001, 10, 207-213.	2.1	16
115	Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, S85-S90.	1.1	9
116	Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab. <i>International Journal of Hematology</i> , 2001, 73, 213-221.	0.7	43
117	A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. <i>British Journal of Haematology</i> , 2001, 113, 375-382.	1.2	335
118	Granular lymphocytic leukemia derived from ATL T-cell expressing cytotoxic molecules. <i>Leukemia Research</i> , 2001, 25, 259-261.	0.4	7
119	Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. <i>Blood</i> , 2000, 95, 2253-61.	0.6	138
120	Long-term Follow-up Results of Adult Patients with Acute Lymphocytic Leukemia or Lymphoblastic Lymphoma Treated with Short-term, Alternating Non-cross-resistant Chemotherapy: Japan Clinical Oncology Group Study 8702. <i>Japanese Journal of Clinical Oncology</i> , 1999, 29, 340-348.	0.6	13
121	Unexpected Hepatotoxicities in Patients with Non-Hodgkin's Lymphoma Treated with Irinotecan (CPT-11) and Etoposide. <i>Japanese Journal of Clinical Oncology</i> , 1998, 28, 502-506.	0.6	15
122	Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8). <i>Journal of Clinical Oncology</i> , 1998, 16, 1440-1444.	0.6	144
123	Adult T-Cell Leukemia-Lymphoma Successfully Treated with 2-Chlorodeoxyadenosine. <i>Internal Medicine</i> , 1998, 37, 411-413.	0.3	7
124	Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. <i>Japanese Journal of Clinical Oncology</i> , 1997, 27, 146-153.	0.6	16
125	Combination Phase I/II Study of Irinotecan Hydrochloride (CPT-11) and Carboplatin in Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 1996, 26, 455-460.	0.6	17
126	Interferon Alfa and Zidovudine in Adult T-Cell Leukemia-Lymphoma. <i>New England Journal of Medicine</i> , 1995, 333, 1285-1286.	13.9	25

#	ARTICLE	IF	CITATIONS
127	Toxicity Grading Criteria of the Japan Clinical Oncology Group. Japanese Journal of Clinical Oncology, 1993, 23, 250-257.	0.6	170
128	Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Japanese Journal of Clinical Oncology, 1993, 23, 250-7.	0.6	60
129	Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group. Japanese Journal of Clinical Oncology, 1992, 22, 164-71.	0.6	34
130	The effect of vitamin D2 on hypocalcemia in patients under chronic hemodialysis.. Tohoku Journal of Experimental Medicine, 1980, 131, 249-255.	0.5	1